Like ALKBH5, FTO is downregulated as a tumor suppressor in a variety of cancers, including BC (145), lung cancer (212), CRC (213), bladder cancer (214, 215), prostate cancer (216), ccRCC (181, 217, 218), and adrenocortical cancer (219). Here, FTO is linked to urinary bladder carcinoma.